| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Antonio M Caballero-Mateos, Claudio Trigo-Salado, Álvaro Suárez-Toribio, María del Mar Martín-Rodríguez, Francisco J Rodríguez-González, Teresa Valdés-Delgado, Héctor Pallarés-Manrique, Ana María Trapero-Martínez, Raúl Olmedo-Martín, Cristina Bailón-Gaona, José Manuel Benitez Cantero, B Gros, Antonia Sáez-Díaz and Álvaro Hernández-Martínez |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Antonio M Caballero-Mateos, MD, PhD, Department of Internal Medicine, Santa Ana Hospital, Motril, Granada, Spain, Avenida Enrique Martín Cuevas s/n,, Motril 18600, Spain. ogy1492@hotmail.com |
| Key Words |
Filgotinib; Ulcerative colitis; JAK inhibitor; Real-world evidence; Effectiveness; Safety |
| Core Tip |
This multicenter real-world study (FILGUITO) evaluated 12-month effectiveness and safety of filgotinib in 104 patients with moderate-to-severe ulcerative colitis, predominantly biologic-experienced. Clinical remission remained sustained at approximately 60% throughout follow-up, with clinical-biochemical remission reaching 38.6% at 6 months. Fecal calprotectin decreased significantly from 2000 μg/g to 153 μg/g at 12 months. Treatment discontinuation occurred in 22.1% of patients. Patients with fewer prior biologic failures showed superior outcomes. Filgotinib demonstrated sustained effectiveness and favorable safety over 12 months, with optimal benefit when used earlier in the treatment algorithm. |
| Publish Date |
2026-02-02 07:26 |
| Citation |
Caballero-Mateos AM, Trigo-Salado C, Suárez-Toribio Á, Martín-Rodríguez MDM, Rodríguez-González FJ, Valdés-Delgado T, Pallarés-Manrique H, Trapero-Martínez AM, Olmedo-Martín R, Bailón-Gaona C, Benitez Cantero JM, Gros B, Sáez-Díaz A, Hernández-Martínez Á. Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study. World J Gastroenterol 2026; 32(6): 115941 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i6/115941.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i6.115941 |
